Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.655 USD | +2.16% | -18.47% | +8.17% |
Financials (USD)
Sales 2024 * | 25.81M | Sales 2025 * | 77.52M | Capitalization | 399M |
---|---|---|---|---|---|
Net income 2024 * | -186M | Net income 2025 * | -163M | EV / Sales 2024 * | 15.5 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.15 x |
P/E ratio 2024 * |
-2.28
x | P/E ratio 2025 * |
-2.56
x | Employees | 285 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.99% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
1 day | -4.42% | ||
1 week | -19.80% | ||
Current month | -32.50% | ||
1 month | -37.69% | ||
3 months | +18.25% | ||
6 months | +29.60% | ||
Current year | +5.88% |
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 14-07-06 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 98-12-31 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-08-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-01-31 |
Ray Debbane
CHM | Chairman | 69 | 07-07-31 |
Director/Board Member | 65 | 07-08-27 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +4.75% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 1.655 | +2.16% | 642 585 |
24-04-17 | 1.62 | -4.42% | 5,561,536 |
24-04-16 | 1.695 | -9.36% | 4,591,788 |
24-04-15 | 1.87 | -5.08% | 3,492,458 |
24-04-12 | 1.97 | -2.96% | 1,870,255 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.88% | 399M | |
-3.39% | 102B | |
+2.61% | 96.84B | |
-0.93% | 21.48B | |
-18.14% | 20.82B | |
-7.29% | 18.6B | |
-40.70% | 16.81B | |
-26.89% | 13.78B | |
+1.12% | 13.4B | |
+22.25% | 11.06B |
- Stock Market
- Equities
- LXRX Stock